Plainsboro, NJ, United States of America

Yingzhi Bi

USPTO Granted Patents = 24 (Patent Applications = 13)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 4.9

ph-index = 7

Forward Citations = 111(Granted Patents)

Company Filing History:

15 out of 3,685

Bristol-myers Squibb Compnay

patents

8 out of 86

Lexicon Pharmaceuticals, Inc.

patents

4 out of 57

Arbutus Biopharma Corporation

patents

where one patent can have more than one assignee

Years Active: 2003-2024

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12083118 - Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same (2024-09-10),

2. 11130740 - Substituted 2,3-dihydro-1H-indene analogs and methods using same (2021-09-28),

3. 11013726 - Substituted pyridinone-containing trycyclic compounds, and methods using same (2021-05-25),

4. 10821103 - Substituted pyridinone-containing trycyclic compounds, and methods using same (2020-11-03),

5. 9862724 - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use (2018-01-09),

6. 9682982 - Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use (2017-06-20),

7. 9403832 - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use (2016-08-02),

8. 8969565 - Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use (2015-03-03),

9. 8946415 - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use (2015-02-03),

10. 8497271 - Modulators of G protein-coupled receptor 88 (2013-07-30),

11. 8426414 - Modulators of G protein-coupled receptor 88 (2013-04-23),

12. 8304577 - Modulators of G protein-coupled receptor 88 (2012-11-06),

13. 7989640 - Sulfonylpyrrolidine modulators of androgen receptor function and method (2011-08-02),

14. 7820702 - Sulfonylpyrrolidine modulators of androgen receptor function and method (2010-10-26),

15. 7772267 - Bicyclic modulators of androgen receptor function (2010-08-10),

Title: The Innovative Contributions of Yingzhi Bi

Introduction

Yingzhi Bi, based in Plainsboro, NJ, has made significant strides in the field of biomedical innovation, holding an impressive total of 24 patents. His work primarily focuses on compounds that offer potential treatments for viral infections, particularly hepatitis B and D viruses.

Latest Patents

Among Yingzhi Bi's latest patents, two stand out for their potential medical applications. The first patent, titled "Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same," presents compositions that are designed to treat or prevent hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The second patent, "Substituted 2,3-dihydro-1H-indene analogs and methods using same," details similar compositions aimed at addressing HBV infections. Both inventions reflect Bi’s commitment to developing effective therapies for serious health issues.

Career Highlights

Yingzhi Bi has had a notable career, contributing his expertise to leading pharmaceutical companies. He has worked with Bristol-Myers Squibb Company, where he was involved in the research and development of new therapeutics. Additionally, his tenure at Lexicon Pharmaceuticals, Inc. has further solidified his role in the innovation landscape of the pharmaceutical industry.

Collaborations

Throughout his career, Yingzhi Bi has collaborated with prominent figures in his field, including his coworkers John E. Macor and Michael Alan Green. These collaborations have been instrumental in advancing his research projects and expanding the impact of his inventions.

Conclusion

Yingzhi Bi's innovative work and numerous patents illustrate his significant contributions to biomedical research. His focus on treating viral infections positions him as a key player in the advancement of medical therapies. As he continues to innovate, the potential benefits of his inventions for public health remain promising.

This text is generated by artificial intelligence and may not be accurate.